Coupling to a glioblastoma-directed antibody potentiates antitumor activity of curcumin

International Journal of Cancer

Volumn 135, Issue 3, 2014, Pages 710-719

  Langone, Phyllis ^a   Debata, Priya Ranjan ^b   Inigo, Joseph Del Rosario ^b   Dolai, Sukanta ^a   Mukherjee, Sumit ^a   Halat, Peter ^b   Mastroianni, Kristina ^b   Curcio, Gina Marie ^b   Castellanos, Mario R ^c   Raja, Krishnaswami ^a   Banerjee, Probal ^b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c CUNY Doctoral Program in Chemistry City University of New York College of Staten Island ^*  (United States)

Author keywords

Akt 1; Brain tumor; Cancer; Curcumin; NF B; Targeting

Indexed keywords

ANTINEOPLASTIC AGENT; CD68 ANTIGEN; CURCUMIN; CURCUMIN CD68 ANTIBODY CONJUGATE; CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL XL; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG EFFICACY; DRUG POTENCY; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR VOLUME;

AKT-1; BRAIN TUMOR; CANCER; CURCUMIN; NF-ΚB; TARGETING;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CURCUMIN; DRUG SYNERGISM; GLIOBLASTOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84900989852     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28555     Document Type: Article

References (32)

1. Ferlay J, Bray F, Pisani P, et al. Globocan 2000: cancer incidence, mortality and prevalence worldwideed. Lyon: IARC Press, 2000.
2. Ohgaki H, Kleihues P,. Epidemiology and etiology of gliomas. Acta Neuropathol 2005; 109: 93-108.
3. Campbell TC, Campbell TM, II,. The China study. Dallas, TX: Benbella Books, 2006.
4. Anand P, Sundaram C, Jhurani S, et al. Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett 2008; 267: 133-64.
5. Carter A,. Curry compound fights cancer in the clinic. J Natl Cancer Inst 2008; 100: 616-17.
6. Chen A, Xu J, Johnson AC,. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene 2005; 25: 278-87.
7. Kunnumakkara AB, Anand P, Aggarwal BB,. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 2008; 269: 199-225.
8. Purkayastha S, Berliner A, Fernando SS, et al. Curcumin blocks brain tumor formation. Brain Res 2009; 1266C: 130-8.
9. Langone P, Debata PR, Dolai S, et al. Coupling to a cancer cell-specific antibody potentiates tumoricidal properties of curcumin. Int J Cancer 2012; 131: E569-E578.
10. Senter PD,. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009; 13: 235-44.
11. Karin M, Cao Y, Greten FR, et al. NH-kB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-10.
12. Shi W, Dolai S, Rizk S, et al. Synthesis of monofunctional curcumin derivatives, clicked curcumin dimer, and a PAMAM dendrimer curcumin conjugate for therapeutic applications. Org Lett 2007; 9: 5461-4.
13. Cline GW, Hanna SB,. The aminolysis of N-hydroxysuccinimide esters. A structure-reactivity study. J Am Chem Soc 1987; 109: 3087-91.
14. Hermanson GT,. Tags and probes bioconjugate techniques. San Diego, CA: Academic Press, 1996. 306.
15. Raja KS, Wang Q, Gonzalez J, et al. Hybrid virus-polymer materials. 1. Synthesis and properties of PEG-decorated cowpea mosaic virus. Biomacromolecules 2003; 4: 472-6.
16. Paxinos G, Franklin KBJ,. The mouse brain in stereotaxic coordinates, 2nd edn. New York: Academic Press, 2001.
17. Deininger MH, Seid K, Engel S, et al. Allograft inflammatory factor 1 defines a distinct subset of infiltrating macrophages/microglial cells in rat and human gliomas. Acta Neuropathol 2000; 100: 673-80.
18. Svensson M, Yadav M, Holmqvist B, et al. Acute pyelonephritis and renal scarring are caused by dysfunctional innate immunity in mCxcr2 heterozygous mice. Kidney Int 2011; 80: 1064-72.
19. Hulette CM, Downey BT, Burger PC,. Macrophage markers in dagnostic neuropathology. Am J Surg Pathol 1992; 16: 493-9.
20. Leenstra S, Das PK, Troost D, et al. Human malignant astrocytes exress macrophage phenotype. J Neuroimmunol 1995; 56: 17-25.
21. Strojnik T, Kavalar R, Zajc I, et al. Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res 2009; 29: 3269-80.
22. Haney SM, Thompson PM, Cloughesy TF, et al. Tracking tumor growth rates in patients with malignant gliomas: a test of two algorithms. Am J Neuroradiol 2001; 22: 73-82.
23. Drug Record: Temozolomide. In: NIDDK, ed. Clinical and Research Information on Drug-Induced Liver Injury: United States Library of Medicine, 2012.
24. Takano T, Lin JH, Arcuino G, et al. Glutamata release promotes growth of malignant gliomas. Nat Med 2001; 7: 1010-15.
25. Grondin R, Zhang Z, Ai Y, et al. Intracranial delivery of proteins and peptides as a therapy for neurodegenerative diseases. Pro Drug Res 2003; 61: 101-23.
26. Burkhardt JK, Riina HA, Shin BJ, et al. Intra-arterial chemotherapy for malignant gliomas: a critical analysis. Interv Neuroradiol 2011; 17: 286-95.
27. Grady D,. A direct hit of drugs to treat brain cancer. The New York Times, 2010.
28. McCafferty J, Griffiths A, Winter G, et al. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348: 552-4.
29. Lonberg N,. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23: 1117-25.
30. Reichert JM, Rosensweig CJ, Faden LB, et al. Monoclonal antibody successes in the clinic. Nat Biotechnol 2005; 23: 1073-8.
31. Reichert JM, Valge-Archer VE,. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6: 349-56.
32. Cassady JM, Chan KK, Floss HG, et al. Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull (Tokyo) 2004; 52: 1-26.